A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer.

Shen Q, Polom K, Williams C, de Oliveira FMS, Guergova-Kuras M, Lisacek F, Karlsson NG, Roviello F, Kamali-Moghaddam M

EBioMedicine 44 (-) 322-333 [2019-06-00; online 2019-05-28]

Gastric cancer (GC) is the third leading cause of cancer death. Early detection is a key factor to reduce its mortality. We retrospectively collected pre- and postoperative serum samples as well as tumour tissues and adjacent normal tissues from 100 GC patients. Serum samples from non-cancerous patients were served as controls (n = 50). A high-throughput protein detection technology, multiplex proximity extension assays (PEA), was applied to measure levels of over 300 proteins. Alteration of each protein was analysed by univariate analysis. Elastic-net logistic regression was performed to select serum proteins into the diagnostic model. We identified 19 serum proteins (CEACAM5, CA9, MSLN, CCL20, SCF, TGF-alpha, MMP-1, MMP-10, IGF-1, CDCP1, PPIA, DDAH-1, HMOX-1, FLI1, IL-7, ZBTB-17, APBB1IP, KAZALD-1, and ADAMTS-15) that together distinguish GC cases from controls with a diagnostic sensitivity of 93%, specificity of 100%, and area under receiver operating characteristic curve (AUC) of 0·99 (95% CI: 0·98-1). Moreover, the 19-serum protein signature provided an increased diagnostic capacity in patients at TNM I-II stage (sensitivity 89%, specificity 100%, AUC 0·99) and in patients with high microsatellite instability (MSI) (91%, 98%, and 0·99) compared to individual proteins. These promising results will inspire a large-scale independent cohort study to be pursued for validating the proposed protein signature. Based on targeted proteomics and elastic-net logistic regression, we identified a 19-serum protein signature which could contribute to clinical GC diagnosis, especially for patients at early stage and those with high MSI. FUND: This study was supported by a European H2020-Marie Skłodowska-Curie Innovative Training Networks grant (316,929, GastricGlycoExplorer). Funder had no influence on trial design, data evaluation, and interpretation.

Affinity Proteomics Uppsala [Technology development]

Bioinformatics Support for Computational Resources [Service]

Clinical Biomarkers [Service]

Glycoproteomics and MS Proteomics [Collaborative]

PLA and Single Cell Proteomics [Technology development]

PubMed 31151932

DOI 10.1016/j.ebiom.2019.05.044

Crossref 10.1016/j.ebiom.2019.05.044

pii: S2352-3964(19)30352-4
pmc: PMC6606959

Publications 9.5.0